GENE ONLINE|News &
Opinion
Blog

2022-04-27| Trials & Approvals

CRISPR Biotech Editas Obtains FDA Rare Pediatric Disease Label

by Fujie Tham
Share To

Cambridge, MA-based Editas Medicine recently announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease designation to EDIT-301, an investigational, gene-edited medicine for treating beta thalassemia. Beta thalassemia is a blood disorder that reduces hemoglobin production, the protein responsible for carrying oxygen.

Following their first designation for treating sickle cell disease, this second FDA label will lead to initiation of Phase I/II study of EDIT-301 in transfusion-dependent beta thalassemia patients this year.

Related Article: Landmark CRISPR Trial Shows Promise Against Fighting Blindness, but Is It a Cure?

 

Editas’ EDIT-301

 

EDIT-301 is an experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). This therapeutic consists of patient-derived CD34+ hematopoietic stem and progenitor cells edited at the gamma globin genes (HBG1, HBG2) promoters, with potential to provide a one-time, persistent treatment benefit for people living with severe sickle cell disease and transfusion-dependent beta thalassemia.

Currently, Editas boasts 10 pipelines revolving around in-vivo gene-edited medicines and ex-vivo gene-edited cell medicines, with research and development efforts focused on diseases which there are currently few or no treatments available. Under its Ex Vivo Gene Edited Cell Medicines catalog, Editas is in partnership with Bristol-Myers Squibb to develop the next generation of ex-vivo gene-edited cell medicines for cancer immunotherapy. 

Editas Medicine was featured as one of GeneOnline’s 10 top gene therapy companies to look out for in 2021.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
This One-Time Injection Could Cure AIDS
2022-06-21
R&D
Massive Human CRISPR-Based Genotype-Phenotype Map Is Now Complete
2022-06-13
Bayer Terminates CAR T-Cell Deal With Atara After Patient Death
2022-05-20
LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top